PL2028937T3 - Leczenie za pomocą agonisty melatoniny - Google Patents

Leczenie za pomocą agonisty melatoniny

Info

Publication number
PL2028937T3
PL2028937T3 PL07797634T PL07797634T PL2028937T3 PL 2028937 T3 PL2028937 T3 PL 2028937T3 PL 07797634 T PL07797634 T PL 07797634T PL 07797634 T PL07797634 T PL 07797634T PL 2028937 T3 PL2028937 T3 PL 2028937T3
Authority
PL
Poland
Prior art keywords
agonist treatment
melatonin agonist
melatonin
treatment
agonist
Prior art date
Application number
PL07797634T
Other languages
English (en)
Other versions
PL2028937T5 (pl
Inventor
Gunther Birznieks
Deepak Phadke
Mihael H Polymeropoulos
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2028937(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of PL2028937T3 publication Critical patent/PL2028937T3/pl
Publication of PL2028937T5 publication Critical patent/PL2028937T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
PL07797634T 2006-05-22 2007-05-22 Leczenie za pomocą agonisty melatoniny PL2028937T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74784706P 2006-05-22 2006-05-22
PCT/US2007/069411 WO2007137244A1 (en) 2006-05-22 2007-05-22 Melatonin agonist treatment
EP07797634.8A EP2028937B2 (en) 2006-05-22 2007-05-22 Melatonin agonist treatment

Publications (2)

Publication Number Publication Date
PL2028937T3 true PL2028937T3 (pl) 2015-10-30
PL2028937T5 PL2028937T5 (pl) 2018-12-31

Family

ID=38723632

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07797634T PL2028937T5 (pl) 2006-05-22 2007-05-22 Leczenie za pomocą agonisty melatoniny

Country Status (17)

Country Link
US (7) US20090105333A1 (pl)
EP (1) EP2028937B2 (pl)
JP (5) JP2009538332A (pl)
KR (2) KR101587394B1 (pl)
AU (3) AU2007253701A1 (pl)
BR (1) BRPI0712206A2 (pl)
CA (2) CA2950087A1 (pl)
CY (1) CY1120433T1 (pl)
DK (1) DK2028937T4 (pl)
ES (1) ES2532849T5 (pl)
MX (1) MX2008014841A (pl)
NL (1) NL300795I2 (pl)
PL (1) PL2028937T5 (pl)
PT (1) PT2028937E (pl)
RU (1) RU2488392C2 (pl)
WO (1) WO2007137244A1 (pl)
ZA (1) ZA200809529B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) † 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
JP5590676B2 (ja) * 2007-09-13 2014-09-17 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｐｅｒ３ｖｎｔｒ遺伝子型に基づく睡眠パラメータ及び睡眠誘導化合物に対する応答の予測
US20120136050A1 (en) * 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
CA3085116C (en) 2012-01-26 2022-07-19 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN110200958A (zh) * 2012-12-18 2019-09-06 万达制药公司 昼夜节律紊乱的治疗
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20170048541A (ko) 2014-09-02 2017-05-08 반다 파마슈티칼즈, 인코퍼레이티드. 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
WO2019028245A1 (en) 2017-08-02 2019-02-07 Vanda Pharmaceuticals Inc. USE OF TASIMELTÉON FOR THE TREATMENT OF AFFECTIVE DISORDERS
AU2019232702A1 (en) 2018-03-04 2020-09-03 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
JP7432884B2 (ja) * 2018-03-26 2024-02-19 パナソニックＩｐマネジメント株式会社 サポートシステム、機器制御システム、サポートシステムの作動方法、及び、機器制御システムの作動方法
SG11202101828PA (en) * 2018-09-12 2021-04-29 Vanda Pharmaceuticals Inc Improving sleep or post-sleep performance
SG11202108695QA (en) * 2019-02-13 2021-09-29 Vanda Pharmaceuticals Inc Method of improving sleep
MX2021016059A (es) * 2019-06-29 2022-02-03 Vanda Pharmaceuticals Inc Uso de tasimelteón en el tratamiento de trastornos del sueño.
IL292492A (en) * 2019-12-13 2022-06-01 Vanda Pharmaceuticals Inc Liquid formulations of tazimalthion and methods of using them

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US5242941A (en) † 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
CZ279797A3 (cs) * 1995-03-06 1998-01-14 Novo Nordisk A/S Způsob stimulace miózy zárodečné buňky a použití sloučeniny, která způsobuje akumulaci látky aktivující endogenní miózu
NZ335910A (en) * 1996-12-10 2000-11-24 Bristol Myers Squibb Co Benzodioxole, benzofuran, dihydrobenzofuran and benzodioxane melatonergic agents useful in treating sleep disorders and circadian rhthym related disorders
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
WO2005063240A1 (en) * 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
KR101146807B1 (ko) * 2005-07-29 2012-05-21 반다 파마슈티칼즈, 인코퍼레이티드. 각성을 향상시키는 방법
KR101587394B1 (ko) † 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
CA3085116C (en) * 2012-01-26 2022-07-19 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
EP3105212A1 (en) * 2014-02-12 2016-12-21 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon
EP3212238A1 (en) † 2014-10-28 2017-09-06 Sandoz AG Pharmaceutical composition consisting of ceftaroline fosamil acetic acid solvate particles and arginine particles, both having a specific particle size distribution

Also Published As

Publication number Publication date
EP2028937A1 (en) 2009-03-04
AU2013207585B2 (en) 2016-04-28
EP2028937A4 (en) 2010-06-02
AU2021273588B2 (en) 2023-03-02
KR101587394B1 (ko) 2016-01-21
CA2666293C (en) 2017-01-10
US20240325339A1 (en) 2024-10-03
JP6659072B2 (ja) 2020-03-04
BRPI0712206A2 (pt) 2012-03-13
JP2017031183A (ja) 2017-02-09
NL300795I2 (pl) 2017-03-28
ZA200809529B (en) 2009-12-30
JP2019089812A (ja) 2019-06-13
US20150080464A1 (en) 2015-03-19
PT2028937E (pt) 2015-04-09
ES2532849T3 (es) 2015-04-01
US20230021493A1 (en) 2023-01-26
ES2532849T5 (es) 2018-10-18
US20090105333A1 (en) 2009-04-23
RU2008150622A (ru) 2010-06-27
DK2028937T3 (en) 2015-04-07
JP2018109057A (ja) 2018-07-12
JP6480050B2 (ja) 2019-03-06
US20160354337A1 (en) 2016-12-08
CA2950087A1 (en) 2007-11-29
KR101571163B1 (ko) 2015-11-23
PL2028937T5 (pl) 2018-12-31
DK2028937T4 (en) 2018-09-03
JP6306114B2 (ja) 2018-04-04
KR20090034810A (ko) 2009-04-08
JP2015013875A (ja) 2015-01-22
MX2008014841A (es) 2008-12-05
AU2007253701A1 (en) 2007-11-29
KR20150083932A (ko) 2015-07-20
WO2007137244A1 (en) 2007-11-29
US20200397741A1 (en) 2020-12-24
EP2028937B2 (en) 2018-06-27
EP2028937B1 (en) 2015-01-28
AU2021273588A1 (en) 2021-12-16
CA2666293A1 (en) 2007-11-29
RU2488392C2 (ru) 2013-07-27
CY1120433T1 (el) 2019-07-10
US20180243258A1 (en) 2018-08-30
JP2009538332A (ja) 2009-11-05

Similar Documents

Publication Publication Date Title
ZA200809529B (en) Melatonin agonist treatment
AU2013207585A1 (en) Melatonin agonist treatment
GB0606604D0 (en) Treatment apparatus
GB0624874D0 (en) Treatment
EP1996182A4 (en) CANCER TREATMENT WITH GAMMA SECRETASE INHIBITORS
EP2106814A4 (en) TREATMENT DEVICE
GB2436010B (en) Therapy device
IL196559A0 (en) Combination therapy
GB0610501D0 (en) Garbage-containing apparatus
GB0608334D0 (en) Apparatus
EP2127715A4 (en) HORIZONTALROHRSEDIMENTATIONSTRENNVORRICHTUNG
GB0600692D0 (en) Well treatment
IL196556A0 (en) Combination therapy
EP2054061A4 (en) COMBINATION THERAPY
GB0605445D0 (en) Opphalmic apparatus
ZA200902203B (en) Combination therapy
GB2438385B (en) Surface treatment device
GB0607952D0 (en) Novel treatment
EP2133035A4 (en) TREATMENT DEVICE
GB0604460D0 (en) Treatment
GB0601181D0 (en) Apparatus
EP2088083A4 (en) PACKING STRIP DEVICE
IL196041A0 (en) 5-htp combination therapy
GB0610716D0 (en) Apparatus
GB0607678D0 (en) Apparatus